FindMyKOL
Clinical trialNCT05188729CompletedPhase 2Interventional

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

SponsorVerrica Pharmaceuticals Inc.Enrollment92Basal Cell CarcinomaCancer of the SkinCancer of the Skin, Basal CellCarcinomaSkin Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC). The study is expected to enroll approximately 86 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Therapeutics Clinical Research

    San Diego, California, United States

  • Clearlyderm

    Boca Raton, Florida, United States

  • Life Clinical Trials

    Coral Springs, Florida, United States

  • Florida Center for Dermatology

    Saint Augustine, Florida, United States

  • Gwinnett Dermatology

    Snellville, Georgia, United States

  • Affinity Health

    Oakbrook Terrace, Illinois, United States

  • Dermassociates

    Rockville, Maryland, United States

  • Lawrence J Green, Md Llc

    Rockville, Maryland, United States

  • Activmed Research - Borthwick

    Portsmouth, New Hampshire, United States

  • Upmc St. Margaret

    Pittsburgh, Pennsylvania, United States

  • Austin Institute of Clinical Research - Dripping Springs

    Dripping Springs, Texas, United States

  • Austin Institute of Clinical Research - Houston

    Houston, Texas, United States

  • Austin Institute of Clinical Research - Pflugerville

    Pflugerville, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Part 1: VP-315 3 Day Dosing/WeekPart 2: VP-315 2 Day Dosing/Week - Split DosePart 2: VP-315 3 Day Dosing/Week - Loading DosePart 2: VP-315 3 Day Dosing/Week - No Loading DosePart 2: VP-315 3 Day Dosing/Week - Split Dose
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Feb 2022
Primary completion
15 Apr 2024
Completion
15 Apr 2024
Last update posted
18 Jun 2025
Registered enrollment
92
Registry id
NCT05188729
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.